Patents

US 12612626 B2: siRNA compound that inhibits expression of APOC3

Granted
2026-04-28
Filed
2022-06-24 application 17849382
Type
Utility · 18 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

Nucleic acid products and compositions and their uses are provided. In particular, nucleic acid products are provided that modulate, interfere with, or inhibit APOC3 gene expression. The products can be oligomeric compounds that comprise at least a first region of linked nucleosides having at least a first nucleobase sequence that is at least partially complementary to at least a portion of RNA transcribed from a APOC3 gene, wherein said first nucleobase sequence is selected from the following sequences, or a portion thereof: SEQ ID NOs 1 to 39

Source: PTBLXML, file of 2026-04-28 (ipgb20260428.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
SIRNAOMICS, INC. 12 patentsUS company or organizationGaithersburg, MDSIRNAOMICS, INC. State business registration EXACT high confidence: identical full name and state
Sirnaomics, Inc. Form D issuer EXACT high confidence: identical full name and state
PTBLXML, file of 2026-04-28

Inventors

InventorPlacePatentsPerson pageSource
Dmitry SamarskyGaithersburg, MD30PTBLXML, file of 2026-04-28

CPC categories

SubclassCategoryFirst groupSource
C12NMicroorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture mediaC12N15/113PTBLXML, file of 2026-04-28
A61KPreparations for medical, dental or toiletry purposesA61K31/232PTBLXML, file of 2026-04-28

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2022-11-08Assignment
Assignment of assignor's interest
SAMARSKY, DMITRY signed 2022-09-30SIRNAOMICS, INC. GAITHERSBURG, MD61689/593PASDL, file of 2026-10-15

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.